Uncategorized
Humira extends time to treatment failure in noninfectious uveitis
Humira met its primary endpoint of extending the time to treatment failure in patients with noninfectious uveitis who still experienced intraocular inflammation despite systemic corticosteroid therapy, manufacturer AbbVie announced in a press release at the Association for Research in Vision and Ophthalmology meeting in Denver.The VISUAL-I study, a phase 3 multicenter, double-masked, randomized, placebo-controlled study, included 217 patients with active intermediate uveitis, posterior uveitis or panuveitis while on corticosteroid therapy.